Announcement
Announcement Under Regulation 30 (LODR) - Clarification By The Company 29 Sep - Kaya clarifies preferential issue of 18,24,150 shares at ₹274.10, revised for ESOP dilution and lock-in date.
Source: Bse
Kaya Limited (KAYA)
Small CapPharma stocks · Small cap · NSE
Kaya Limited operates in Beauty & Personal Care, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:10 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage10/14 · 71%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
70BullishSMA20 -7.9% / mo · MACD + · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 50
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
KAYAD candles · FIT view+10.5%Latest close ₹298.50 on 2026-10-21
Bar
-3.1%
RSI
42
MACD hist
0.26
52W pos
30%
2026-10-21O ₹307.90H ₹308.00L ₹296.80C ₹298.50Vol 2,103 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
KAYANifty PharmaNifty 500
- KAYA
- +21.8%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +28.3 pp
Chart stats
21 Oct 2026- From 52W high
- -37.3%
- 52W range position
- 30%
- ATR (14)
- 5.4%
- Volume vs 20D
- 0.33x
- Avg traded value
- ₹0.2 Cr
- 20D price channel
- ₹285.2 - ₹347
₹476.2
₹224 - ₹476.2
₹16
Latest completed session
20-session average
44.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED11
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad22
Revenue +13.2% · PAT NDF YoY
Technical
Bullish70
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence62
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 22/100margin compression · Rev +13% YoY · +7% QoQ
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹60 Cr | +13.2% | +7.1% |
| EBITDA | ₹4 Cr | +0.0% | +130.8% |
| Operating margin | 6.0% | -100 bps | +2900 bps |
| PAT | ₹-15 Cr | NDF | NDF |
| PAT margin | -25.0% | +142 bps | +2500 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- —
- EV/EBITDA
- 34.00
- Market Cap
- 452.00Cr
Profitability
- ROE
- —
- ROCE
- -45.60%
- ROA
- -34.53%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -4.00%
- EPS 5Y
- -9.00%
- Revenue 3Y
- -16.00%
- EPS 3Y
- 6.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- -0.58×
- Altman Z
- 0.32
- Book Value
- -101.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 7/5
- OCF
- 21.00 Cr
- EPS TTM
- -63.32
Shareholding
- Promoter Hold
- 51.43%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 33%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 60.0+7.1% vs prev
Net Profit
₹ CrLatest: -15.0+46.4% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 42.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~8.5% over last month) — short-term momentum negative.
- RSI(14) at 42 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 37% off 52W high · 33% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
55
RS percentile
Stage 3 Topping
1M return
-10.3%
3M return
+21.8%
6M return
+11.0%
1Y return
-30.6%
RS 1D
-4
RS 20D
+2
Sector rank
#1
Industry rank
-
Stage evidence
- 35.0% below the 52-week closing high after prior strength.
- The 30-week proxy has stalled (+0.0% over 20 sessions).
- Price has not yet confirmed a full Stage 4 downtrend.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 67.72-3.55%
RS vs Nifty 50068
Valuation & peers
U-Score 11 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 11 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Distress Watch
Fundamental score breakdown
U band · OVERVALUEDValuation2/30
Growth1/25
Quality0/20
Balance Sheet4/15
Cash Flow4/10
Piotroski
6/9 (+3)
Penalties
-3
Raw sum
11
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
11/100 · legacy band OVERVALUED
Positive drivers
- Cash flow contributes 4/10 to the score.
- Balance sheet contributes 4/15 to the score.
- Valuation contributes 2/30 to the score.
Main drags
- Altman Z is 0.3, in distress territory.
- Penalty bucket subtracts 3 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
—
EV/EBITDA
34.0
ROE
—
ROCE
-45.6%
FCF Yield
—
Debt/Equity
0.0
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
11
Previous: 11
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
11
11
11
11
11
11
11
11
11
11
11
11
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
4.0
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MHHL
SME
Mohini Health & Hygiene Ltd.
Consumer Healthcare
match 125
18
—
-8.9%
—
OVERVALUED
WALPAR
SME
Walpar Nutritions Ltd.
Consumer Healthcare
match 120
64
9.9
13.9%
+78%
UNDERVALUED
AMRUTANJAN
Small
Amrutanjan Health Care Limited
Consumer Healthcare
match 105
52
73.4
20.0%
-113%
FAIR VALUE
MEDICAMEQ
Small
Medicamen Biotech Limited
Pharmaceuticals
match 97
18
38.9
4.0%
-521%
OVERVALUED
HALEOSLABS
Small
HALEOS LABS LIMITED
Pharmaceuticals
match 96
29
29.6
8.4%
-139%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Kaya Limited operates in Beauty & Personal Care, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
62Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 35th percentile of the scored universe and 24th percentile within Pharma. Main check: financial discipline is weak at 48/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
100 docs text-extracted · 34 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
35th percentile
overall median 67 · Pharma: 24th pctile, median 70 · Small: 40th pctile, median 66
Evidence depth
Financial-only
100 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
62
acceptable · leverage and solvency
Discipline
48
watch · capital discipline
Results
50
watch · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸7 years of positive FCF.
- ▸Debt/equity is 0.00.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Altman Z is 0.42.
- ▸ROCE is low at -45.6%.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
- ▸OPM spread across recent quarters is 34%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Kaya Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Aug - Newspaper Publication for the EOGM notice Dispatched on August 12, 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Change in Management 15 Jul - Kaya appoints Vasuta Agarwal as additional independent director; reappointment proposed for August 3, 2026 to August 2, 2031.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 10 Aug - Grant of Employee Stock Option to eligible employee.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Change in Management 10 Jul - Mr. Nikhil Nirvan Khattau resigns as Non-Executive Director effective July 31, 2026.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Change in Management 20 May - Kaya appoints Brijesh Goyal as CFO and KMP effective July 11, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Jul - Post Dispatch of the 23rd AGM Notice Newspaper Publication
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Jul - Pre-Dispatch of the AGM Notice Newspaper publication
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Change in Management 19 Jun - Amrita Chowdhury, VP & Head HR, relieved effective June 19, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 27 May - Grant of ESOPs to eligible employees of the Company under the Employee Stock Option 2021 Scheme-V
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.